See up to 3 months of CTY. The 7-day demo opens the 1M and 3M ranges and puts CTY on your watchlist.
Start 7-day demoLatest CTY insider trades
- ARCH Venture Partners XII, LLC - 10% OwnerOpen-market purchase$3.06M
Robert Nelsen - Director
About CITY THERAPEUTICS, INC. (CTY)
CITY THERAPEUTICS, INC. is an SEC registrant, filing under CIK 0002143850, classified as pharmaceutical preparations. We track it alongside the rest of the Health Care sector. Its offering priced on 16 October 2026 and it trades on NASDAQ.
CTY Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 2 | 340,000 | $6.12M |
| Grant or award | 6 | 191,224 | |
| Other acquisition / disposition | 15 | 42,449,720 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
CTY insider transactions (Form 4)
237 Form 4 filings on record, the earliest from Oct 19, 2026, newest first.
| Traded | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| ARCH Venture Partners XII, LLC - 10% Owner | Other | Common Stock | 3,294,900 | - footnote F1 | - | |
| ARCH Venture Partners XII, LLC - 10% Owner | Other | Common Stock | 5,482,309 | - footnote F1 | - | |
| ARCH Venture Partners XII, LLC - 10% Owner | Other | Common Stock | 2,027,006 | - footnote F1 | - | |
| ARCH Venture Partners XII, LLC - 10% Owner | Open-market purchase | Common Stock | 170,000 | $18.00 | $3.06M | |
| ARCH Venture Partners XII, LLC - 10% Owner | Other | Series Seed convertible preferred stock | 3,000,000 | $0.00 | - | |
| ARCH Venture Partners XII, LLC - 10% Owner | Other | Series A convertible preferred stock | 4,991,633 | $0.00 | - | |
| ARCH Venture Partners XII, LLC - 10% Owner | Other | Series B convertible preferred stock | 1,845,585 | $0.00 | - | |
| ||||||
| Robert Nelsen - Director | Other | Common Stock | 3,294,900 | - footnote F1 | - | |
| Robert Nelsen - Director | Other | Common Stock | 5,482,309 | - footnote F1 | - | |
| Robert Nelsen - Director | Other | Common Stock | 2,027,006 | - footnote F1 | - | |
| Robert Nelsen - Director | Open-market purchase | Common Stock | 170,000 | $18.00 | $3.06M | |
| Robert Nelsen - Director | Grant or award | Stock Option (Right to Buy) | 22,649 | $0.00 | - | |
| Robert Nelsen - Director | Other | Series Seed convertible preferred stock | 3,000,000 | $0.00 | - | |
| Robert Nelsen - Director | Other | Series A convertible preferred stock | 4,991,633 | $0.00 | - | |
| Robert Nelsen - Director | Other | Series B convertible preferred stock | 1,845,585 | $0.00 | - | |
| ||||||
| John Maraganore - Director | Other | Common Stock | 610,759 | - footnote F1 | - | |
| John Maraganore - Director | Grant or award | Stock Option (Right to Buy) | 22,649 | $0.00 | - | |
| John Maraganore - Director | Other | Series Seed convertible preferred stock | 500,000 | $0.00 | - | |
| John Maraganore - Director | Other | Series A convertible preferred stock | 56,095 | $0.00 | - | |
| ||||||
| Sara Nochur - Director | Grant or award | Stock Option (Right to Buy) | 22,649 | $0.00 | - | |
| Andrew C. Orth - Officer | Grant or award | Stock Option (Right to Buy) | 77,979 | $0.00 | - | |
 Ron M. Philip - Director | Grant or award | Stock Option (Right to Buy) | 22,649 | $0.00 | - | |
| Barry E. Greene - Director | Grant or award | Stock Option (Right to Buy) | 22,649 | $0.00 | - | |
CTY insider trading FAQ
What is the latest insider trade for CTY?
CITY THERAPEUTICS, INC. (CTY) had 7 insider filings in the last 90 days, with the most recent on 19 October 2026. The full record for CTY runs to 7 Form 4 filings, the earliest from 19 October 2026. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying CTY stock?
2 insider purchases of CTY were filed in the last 90 days, totaling $6.12M.
How many insiders are selling CTY stock?
No insider sales of CTY were filed in the last 90 days.
Where can I see CTY SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects CTY Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
7The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - ARCH Venture Partners XII, LLC view on EDGAR
- - Robert Nelsen view on EDGAR
- - John Maraganore view on EDGAR
- - Sara Nochur view on EDGAR
- - Andrew C. Orth view on EDGAR
- - Ron M. Philip view on EDGAR
- - Barry E. Greene view on EDGAR
Related companies with recent insider activity
Learn more
- How to read insider buying signals
- What an open-market purchase by an insider can and cannot tell you.
- Insider activity in Health Care
- Where CTY's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow CTY with a 7-day demo
- CTY on your watchlist
- Every CTY Form 4 filing on record
- Up to 3 months of CTY price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
